← Leaderboards
Shalendar Bhasin
La Biomed Res Inst/ Harbor Ucla Med Ctr
$66,433,688
Attributed
$99,575,366
Total exposure
54
Grants
38
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.7M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$120,932,997 · 55
By mechanism
U01$45,948,456 · 5
R01$38,776,543 · 17
P30$27,831,353 · 5
U54$2,526,021 · 1
R44$1,500,000 · 1
T32$1,436,042 · 2
Top collaborators
- Thomas Michael Gill8 shared
- David B. Reuben8 shared
- Caroline M Apovian7 shared
- Vasan S. Ramachandran6 shared
- Peggy Mannen Cawthon4 shared
- Gad Asher Marshall4 shared
- Sushrut S. Waikar3 shared
- Paolo Bonato2 shared
Most similar at La Biomed Res Inst/ Harbor Ucla Med Ctr
Same institution · by research overlap
- C Keith Beck$100,302
Others in their field
Top investigators on “Testosterone”
- Peter J. Snyder · University Of Pennsylvania$39,424,875
- William S Kremen · University Of California Davis$21,636,730
- Susan E. Hankinson · University Of Massachusetts Amherst$19,337,166
- Clint Dart · Health Decisions, Inc.$17,090,158
- Johannes D Veldhuis · University Of Virginia Charlottesville$14,582,703
- Michael P Harms · Washington University$13,645,932
Research focus
TestosteronePhysical FunctionAgingMuscleElderlyProgramsRandomizedMuscle StrengthAmericanResearch PersonnelBasePlacebosCommunitiesTrainingMonitorAffectRandomized TrialQuality Of LifeFundingDisabilityMaleResponseParticipantClinical Trials
Grant awards (194)
Boston OAIC: A Translational Approach to Function Promoting Therapies$1,362,218
P30 · FY2025 · AG · contact PI
Development, Validation, and Harmonization of Methods for Collection and Measurement of NAD+ and Related Metabolites: Application to a Randomized Trial of Patients Undergoing Coronary Artery Bypass$1,213,239
U01 · FY2025 · AG · contact PI
Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People with Down Syndrome$801,359
R01 · FY2025 · AG · contact PI
A Pilot Study to Evaluate the Anabolic Effect of Testosterone on Muscles of the Pelvic Floor in Older Women with Stress Urinary Incontinence$354,840
R01 · FY2025 · DK · contact PI
Leadership and Administrative Core$202,162
P30 · FY2025 · AG · contact PI
Training Program in Patient-Oriented Research in Cardiovascular Endocrinology$201,426
T32 · FY2025 · HL
Boston OAIC: A Translational Approach to Function Promoting Therapies$1,360,451
P30 · FY2024 · AG · contact PI
Development, Validation, and Harmonization of Methods for Collection and Measurement of NAD+ and Related Metabolites: Application to a Randomized Trial of Patients Undergoing Coronary Artery Bypass$1,020,661
U01 · FY2024 · AG · contact PI
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial$857,882
U01 · FY2024 · AG · contact PI
Leadership and Administrative Core$388,751
P30 · FY2024 · AG · contact PI
A Pilot Study to Evaluate the Anabolic Effect of Testosterone on Muscles of the Pelvic Floor in Older Women with Stress Urinary Incontinence$340,646
R01 · FY2024 · DK · contact PI
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease$229,495
R01 · FY2024 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$1,718,896
P30 · FY2023 · AG · contact PI
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease$881,647
R01 · FY2023 · AG · contact PI
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial$868,111
U01 · FY2023 · AG · contact PI
Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency$447,317
R01 · FY2023 · AG · contact PI
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury$446,376
R01 · FY2023 · HD · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$393,694
P30 · FY2023 · AG · contact PI
Leadership and Administrative Core$390,507
P30 · FY2023 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$87,682
P30 · FY2023 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$1,364,110
P30 · FY2022 · AG · contact PI
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury$998,300
R01 · FY2022 · HD · contact PI
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial$899,746
U01 · FY2022 · AG · contact PI
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease$873,053
R01 · FY2022 · AG · contact PI
Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency$721,908
R01 · FY2022 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$426,342
P30 · FY2022 · AG · contact PI
Leadership and Administrative Core$206,495
P30 · FY2022 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$116,910
P30 · FY2022 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$29,228
P30 · FY2022 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$1,397,962
P30 · FY2021 · AG · contact PI
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury$1,030,319
R01 · FY2021 · HD · contact PI
Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency$754,691
R01 · FY2021 · AG · contact PI
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease$752,126
R01 · FY2021 · AG · contact PI
Leadership and Administrative Core$219,272
P30 · FY2021 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$1,143,887
P30 · FY2020 · AG · contact PI
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury$1,051,348
R01 · FY2020 · HD · contact PI
Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency$754,691
R01 · FY2020 · AG · contact PI
Assisted living communities- transforming predictive data into proactive care for COVID-19$371,423
P30 · FY2020 · AG · contact PI
Defining inflammaging and monocyte dysfunction in COVID-19 disease$366,578
P30 · FY2020 · AG · contact PI
Feasibility of Remote Home Support Coaches to Decrease the Physical and Psychological Impact of Social Distancing on Older Adults$325,895
P30 · FY2020 · AG · contact PI
Leadership and Administration Core$231,036
P30 · FY2020 · AG · contact PI
Randomized Trial of a Multifactorial Fall Injury Prevention Strategy-Supplement$2,065,602
U01 · FY2019 · AG · contact PI
Randomized Trial of a Multifactorial Fall Injury Prevention Strategy-Supplement$1,300,000
U01 · FY2019 · AG · contact PI
Randomized Trial of a Multifactorial Fall Injury Prevention Strategy$1,237,359
U01 · FY2019 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$1,143,887
P30 · FY2019 · AG · contact PI
Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency$754,691
R01 · FY2019 · AG · contact PI
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury$739,979
R01 · FY2019 · HD · contact PI
A selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer$699,109
R01 · FY2019 · NR · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$414,750
P30 · FY2019 · AG · contact PI
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury-supplement$331,119
R01 · FY2019 · HD · contact PI
Leadership and Administration Core$230,942
P30 · FY2019 · AG · contact PI
Randomized Trial of a Multifactorial Fall Injury Prevention Strategy$6,693,458
U01 · FY2018 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$1,143,912
P30 · FY2018 · AG · contact PI
Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency$786,191
R01 · FY2018 · AG · contact PI
Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury$735,642
R01 · FY2018 · HD · contact PI
A selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer$687,002
R01 · FY2018 · NR · contact PI
Leadership and Administration Core$230,768
P30 · FY2018 · AG · contact PI
Position Development Conference for Sarcopenia Definitions and Outcomes$50,000
R13 · FY2018 · AG · contact PI
Randomized Trial of a Multifactorial Fall Injury Prevention Strategy$8,416,857
U01 · FY2017 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$1,106,725
P30 · FY2017 · AG · contact PI
A selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer$687,002
R01 · FY2017 · NR · contact PI
Leadership and Administration Core$232,373
P30 · FY2017 · AG · contact PI
Muscle Mass and Strength Cutpoints in Persons at Risk of Mobility Disability-A1$164,566
U01 · FY2017 · AG · contact PI
Anti-Geronic Factors, GDF11 and Oxytocin, and Aging-Related Phenotypes$115,002
R56 · FY2017 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Therapies$1,192,831
P30 · FY2016 · AG · contact PI
Muscle Mass and Strength Cutpoints in Persons at Risk of Mobility Disability$750,739
U01 · FY2016 · AG · contact PI
A Novel System to Detect Falls in Real-life Conditions$750,000
R44 · FY2016 · AG
A selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer$687,002
R01 · FY2016 · NR · contact PI
Anti-Geronic Factors, GDF11 and Oxytocin, and Aging-Related Phenotypes$237,600
R56 · FY2016 · AG · contact PI
Leadership and Administration Core$229,611
P30 · FY2016 · AG · contact PI
Randomized Trial of a Multifactorial Fall Injury Prevention Strategy$6,167,288
U01 · FY2015 · AG · contact PI
Randomized Trial of a Multifactorial Fall Injury Prevention Strategy$1,250,001
U01 · FY2015 · AG · contact PI
A Novel System to Detect Falls in Real-life Conditions$750,000
R44 · FY2015 · AG
Muscle Mass and Strength Cutpoints in Persons at Risk of Mobility Disability$747,785
U01 · FY2015 · AG · contact PI
A selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer$739,632
R01 · FY2015 · NR · contact PI
Randomized Trial of a Multifactorial Fall Injury Prevention Strategy$7,645,479
U01 · FY2014 · AG · contact PI
Optimizing Protein Intake in Older Americans with Mobility Limitations$668,421
R01 · FY2014 · AG · contact PI
Population-Based Reference Ranges for Estradiol and Estrone in Men$530,410
R01 · FY2014 · DK · contact PI
Mechanisms of Testosterone Action$455,020
R01 · FY2014 · AG · contact PI
Optimizing Protein Intake in Older Americans with Mobility Limitations$176,156
R01 · FY2014 · AG · contact PI
Optimizing Protein Intake in Older Americans with Mobility Limitations$811,351
R01 · FY2013 · AG · contact PI
Mechanism of Myostatin Action$772,174
R01 · FY2013 · DK · contact PI
Population-Based Reference Ranges for Estradiol and Estrone in Men$518,107
R01 · FY2013 · DK · contact PI
Mechanisms of Testosterone Action$395,536
R01 · FY2013 · AG · contact PI
Optimizing Protein Intake in Older Americans with Mobility Limitations$50,000
R01 · FY2013 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Anabolic Therapies$1,094,232
P30 · FY2012 · AG · contact PI
Optimizing Protein Intake in Older Americans with Mobility Limitations$847,789
R01 · FY2012 · AG · contact PI
BMC--BHASIN$810,313
P30 · FY2012 · AG · contact PI
Mechanism of Myostatin Action$781,504
R01 · FY2012 · DK · contact PI
Population-Based Reference Ranges for Estradiol and Estrone in Men$557,813
R01 · FY2012 · DK · contact PI
Mechanisms of Testosterone Action$438,555
R01 · FY2012 · AG · contact PI
A multimodality intervention for mobility limitation in older Americans$166,154
R34 · FY2012 · AG · contact PI
Metabolism, Endocrinology and Obesity Training Grant$152,802
T32 · FY2012 · DK · contact PI
Boston OAIC: A Translational Approach to Function Promoting Anabolic Therapies$1,116,770
P30 · FY2011 · AG · contact PI
Optimizing Protein Intake in Older Americans with Mobility Limitations$848,266
R01 · FY2011 · AG · contact PI
BMC--BHASIN$814,436
P30 · FY2011 · AG · contact PI
Mechanism of Myostatin Action$486,196
R01 · FY2011 · DK · contact PI
Mechanisms of Testosterone Action$451,197
R01 · FY2011 · AG · contact PI
TESTOSTERONE SUPPLEMENTATION FOR MEN WITH SARCOPENIA$369,469
U01 · FY2011 · AG · contact PI
Metabolism, Endocrinology and Obesity Training Grant$364,906
T32 · FY2011 · DK · contact PI
Metabolism, Endocrinology and Obesity Training Grant$49,944
T32 · FY2011 · DK · contact PI
Boston OAIC: A Translational Approach to Function Promoting Anabolic Therapies$1,238,458
P30 · FY2010 · AG · contact PI
BMC--BHASIN$842,060
P30 · FY2010 · AG · contact PI
Optimizing Protein Intake in Older Americans with Mobility Limitations$668,443
R01 · FY2010 · AG · contact PI
Mechanism of Myostatin Action$547,934
R01 · FY2010 · DK · contact PI
Population-Based Reference Ranges for Testosterone$479,805
R01 · FY2010 · AG · contact PI
Mechanisms of Testosterone Action$452,083
R01 · FY2010 · AG · contact PI
TESTOSTERONE SUPPLEMENTATION FOR MEN WITH SARCOPENIA$353,660
U01 · FY2010 · AG · contact PI
Metabolism, Endocrinology and Obesity Training Grant$143,925
T32 · FY2010 · DK · contact PI
Mechanism of Myostatin Action$44,000
R01 · FY2010 · DK · contact PI
N-TERMINAL PROPEPTIDE OF TYPE III PROCOLLAGEN AS A BIOMARKER OF ANABOLIC$11,261
P41 · FY2010 · RR · contact PI
Boston OAIC: A Translational Approach to Function Promoting Anabolic Therapies$1,152,434
P30 · FY2009 · AG · contact PI
TESTOSTERONE SUPPLEMENTATION FOR MEN WITH SARCOPENIA$844,191
U01 · FY2009 · AG · contact PI
BMC--BHASIN$773,524
P30 · FY2009 · AG · contact PI
Mechanism of Myostatin Action$531,914
R01 · FY2009 · DK · contact PI
Population-Based Reference Ranges for Testosterone$527,714
R01 · FY2009 · AG · contact PI
Testosterone Modulation of Response to Phosphodiesterase Inhibitors$348,924
R01 · FY2009 · HD · contact PI
Metabolism, Endocrinology and Obesity Training Grant$315,346
T32 · FY2009 · DK · contact PI
Boston OAIC: A Translational Approach to Function Promoting Anabolic Therapies$85,666
P30 · FY2009 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Anabolic Therapies$68,692
P30 · FY2009 · AG · contact PI
Boston OAIC: A Translational Approach to Function Promoting Anabolic Therapies$1,133,998
P30 · FY2008 · AG · contact PI
TESTOSTERONE SUPPLEMENTATION FOR MEN WITH SARCOPENIA$757,491
U01 · FY2008 · AG · contact PI
BMC--BHASIN$671,472
P30 · FY2008 · AG · contact PI
Population-Based Reference Ranges for Testosterone$412,814
R01 · FY2008 · AG · contact PI
Testosterone Modulation of Response to Phosphodiesterase Inhibitors$320,162
R01 · FY2008 · HD · contact PI
Metabolism, Endocrinology and Obesity Training Grant$207,693
T32 · FY2008 · DK · contact PI
TESTOSTERONE SUPPLEMENTATION FOR MEN WITH SARCOPENIA$160,230
U01 · FY2008 · AG · contact PI
TESTOSTERONE SUPPLEMENTATION FOR MEN WITH SARCOPENIA$762,243
U01 · FY2007 · AG · contact PI
Mechanisms of Testosterone Effects on Body Composition$358,745
R01 · FY2007 · DK · contact PI
Role of 5-alpha Reductase in Testosterone Actions$333,299
R01 · FY2007 · HD · contact PI
Testosterone Modulation of Response to Phosphodiesterase Inhibitors$318,547
R01 · FY2007 · HD · contact PI
THE ROLE OF 5 ALPHA REDUCTASE IN MEDIATING TESTOSTERONE ACTION$188,217
M01 · FY2007 · RR · contact PI
TESTOSTERONE DOSE RESPONSE IN SURGICALLY MENOPAUSAL WOMEN$137,516
M01 · FY2007 · RR · contact PI
TESTOSTERONE REPLACEMENT AND PHYSICAL FUNCTION IN HIV+ MEN$47,463
P20 · FY2007 · RR · contact PI
TESTOSTERONE REPLACEMENT ON MUSCLE PERFORMANCE & PHYSICAL FUNC IN MEN$43,408
M01 · FY2007 · RR · contact PI
TESTOSTERONE REPLACEMENT ON ATHEROSCLEROSIS PROGRESSION IN OLDER MEN$20,489
M01 · FY2007 · RR · contact PI
ANDROGEN MODULATION OF PHOSPHODIESTERASE INHIBITORS IN ERECTILE DYSFUNCTION$1,389
M01 · FY2007 · RR · contact PI
TESTOSTERONE SUPPLEMENTATION FOR MEN WITH SARCOPENIA$773,566
U01 · FY2006 · AG · contact PI
Mechanisms of Testosterone Effects on Body Composition$369,460
R01 · FY2006 · DK · contact PI
Role of 5-alpha Reductase in Testosterone Actions$343,254
R01 · FY2006 · HD · contact PI
Testosterone Modulation of Response to Phosphodiesterase Inhibitors$320,831
R01 · FY2006 · HD · contact PI
TESTOSTERONE SUPPLEMENTATION FOR MEN WITH SARCOPENIA$56,801
U01 · FY2006 · AG · contact PI
TESTOSTERONE DOSE RESPONSE IN SURGICALLY MENOPAUSAL WOMEN$28,181
M01 · FY2006 · RR · contact PI
THE ROLE OF 5 ALPHA REDUCTASE IN MEDIATING TESTOSTERONE ACTION$18,144
M01 · FY2006 · RR · contact PI
OLDER MEN AS RESPONSIVE AS YOUNG MEN TO ANABOLIC EFFECTS OF TESTOSTERONE$5,897
P41 · FY2006 · RR · contact PI
EFFECTS OF TESTOSTERONE REPLACEMENT ON MUSCLE PERFORMANCE & PHYSICAL FUNC IN MEN$3,860
M01 · FY2006 · RR · contact PI
TESTOSTERONE SUPPLEMENTATION FOR MEN WITH SARCOPENIA$572,032
U01 · FY2005 · AG
HORMONE ASSAY CORE$494,538
P20 · FY2005 · RR
TESTOSTERONE REPLACEMENT &PHYSICAL FUNCTION IN HIV+MEN$441,471
R01 · FY2005 · DK
Mechanisms of Testosterone Effects on Body Composition$378,350
R01 · FY2005 · DK
Role of 5-alpha Reductase in Testosterone Actions$339,802
R01 · FY2005 · HD
Testosterone Modulation of Response to Phosphodiesterase Inhibitors$311,676
R01 · FY2005 · HD
HORMA$19,782
P20 · FY2005 · RR
THE ROLE OF 5-ALPHA REDUCTASE IN MEDIATING ANDROGEN ACTION$19,782
P20 · FY2005 · RR
TESTOSTERONE REPLACEMENT AND PHYSICAL FUNCTION IN HIV+ MEN$19,782
P20 · FY2005 · RR
TESTOSTERONE REPLACEMENT, PHYSICAL FUNCTION AND HEMODIALYSIS$19,782
P20 · FY2005 · RR
OLDER MEN ARE AS RESPONSIVE AS YOUNGER MEN TO THE ANABOLIC EFFECTS OF GRAD$6,475
P41 · FY2005 · RR
THE BIOLOGIC EFFECTS OF ANDROGENS IN MEN AND WOMEN$1,224,923
U54 · FY2004 · HD
Hormone Assay Core$471,099
P20 · FY2004 · RR
TESTOSTERONE REPLACEMENT &PHYSICAL FUNCTION IN HIV+MEN$381,437
R01 · FY2004 · DK
Mechanisms of Testosterone Effects on Body Composition$378,350
R01 · FY2004 · DK
Role of 5-alpha Reductase in Testosterone Actions$320,625
R01 · FY2004 · HD
Testosterone:Physical Function in Men on Hemodialysis$286,687
R01 · FY2004 · DK
Testosterone:Physical Function in Men on Hemodialysis$125,317
R01 · FY2004 · DK
TESTOSTERONE REPLACEMENT &PHYSICAL FUNCTION IN HIV+MEN$86,448
R01 · FY2004 · DK
THE BIOLOGIC EFFECTS OF ANDROGENS IN MEN AND WOMEN$65,550
U54 · FY2004 · HD
Role of 5-alpha Reductase in Testosterone Actions$51,916
R01 · FY2004 · HD
TESTOSTERONE REPLACEMENT &PHYSICAL FUNCTION IN HIV+MEN$20,663
R01 · FY2004 · DK
Role of 5-alpha Reductase in Mediating Androgen Action$18,851
P20 · FY2004 · RR
TESTOSTERONE REPLACEMENT,PHYSICAL FUNCTION &HEMODIALYSIS$18,851
P20 · FY2004 · RR
HORMA$18,851
P20 · FY2004 · RR
TESTOSTERONE REPLACEMENT &PHYSICAL FUNCTION IN HIV+ MEN$15,328
P20 · FY2004 · RR
THE BIOLOGIC EFFECTS OF ANDROGENS IN MEN AND WOMEN$1,235,548
U54 · FY2003 · HD
TESTOSTERONE REPLACEMENT &PHYSICAL FUNCTION IN HIV+MEN$424,580
R01 · FY2003 · DK
Testosterone:Physical Function in Men on Hemodialysis$412,688
R01 · FY2003 · DK
Role of 5-alpha Reductase in Testosterone Actions$320,625
R01 · FY2003 · HD
Testosterone:Physical Function in Men on Hemodialysis$40,000
R01 · FY2003 · DK
Testosterone:Physical Function in Men on Hemodialysis$408,057
R01 · FY2002 · DK
TESTOSTERONE REPLACEMENT &PHYSICAL FUNCTION IN HIV+MEN$358,946
R01 · FY2002 · DK
SARCOPENIA--TESTOSTERONE DOSE RESPONSE IN OLDER MEN$50,000
R01 · FY2002 · AG
CORE--HORMONE ASSAY$0
P20 · FY2002 · RR
Testosterone:Physical Function in Men on Hemodialysis$398,204
R01 · FY2001 · DK
SARCOPENIA--TESTOSTERONE DOSE RESPONSE IN OLDER MEN$391,484
R01 · FY2001 · AG
TESTOSTERONE REPLACEMENT, RESISTANCE EXERCISE IN HIV WASTING SYNDROME$237,978
M01 · FY2001 · RR
IDIOPATHIC HYPOGONADOTROPHIC HYPOGONADISM TREATMENT W/RECOMBINANT FSH$237,978
M01 · FY2001 · RR
OXANDROLONE ON BODY WEIGHT AND COMPOSITION$237,978
M01 · FY2001 · RR
CORE--HORMONE ASSAY$0
P20 · FY2001 · RR
SARCOPENIA--TESTOSTERONE DOSE RESPONSE IN OLDER MEN$397,308
R01 · FY2000 · AG
IDIOPATHIC HYPOGONADOTROPHIC HYPOGONADISM TREATMENT W/RECOMBINANT FSH$982
M01 · FY2000 · RR
OXANDROLONE ON BODY WEIGHT AND COMPOSITION$982
M01 · FY2000 · RR
TESTOSTERONE REPLACEMENT, RESISTANCE EXERCISE IN HIV WASTING SYNDROME$982
M01 · FY2000 · RR
TESTOSTERONE REPLACEMENT, RESISTANCE EXERCISE IN HIV WASTING SYNDROME$0
M01 · FY2000 · RR
CORE--HORMONE ASSAY$0
P20 · FY2000 · RR
TESTOSTERONE REPLACEMENT, RESISTANCE EXERCISE IN HIV WASTING SYNDROME$0
M01 · FY2000 · RR